PharmaEngine (TWO:4162) — Market Cap & Net Worth
Market Cap & Net Worth: PharmaEngine (4162)
PharmaEngine (TWO:4162) has a market capitalization of $245.05 Million (NT$7.78 Billion) as of May 4, 2026. Listed on the TWO stock exchange, this Taiwan-based company holds position #15764 globally and #712 in its home market, demonstrating a -4.02% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying PharmaEngine's stock price NT$54.90 by its total outstanding shares 141677000 (141.68 Million). Analyse 4162 cash flow metrics to see how efficiently the company converts income to cash.
PharmaEngine Market Cap History: 2015 to 2026
PharmaEngine's market capitalization history from 2015 to 2026. Data shows change from $629.29 Million to $245.05 Million (-7.69% CAGR).
PharmaEngine Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how PharmaEngine's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.16x
PharmaEngine's market cap is 0.16 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.23x
PharmaEngine's market cap is 0.23 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $629.29 Million | $507.24 Million | $394.02 Million | 1.24x | 1.60x |
| 2016 | $573.98 Million | $1.13 Billion | $689.62 Million | 0.51x | 0.83x |
| 2017 | $584.01 Million | $853.68 Million | $387.06 Million | 0.68x | 1.51x |
| 2018 | $439.37 Million | $293.43 Million | $129.36 Million | 1.50x | 3.40x |
| 2019 | $270.03 Million | $314.04 Million | $42.55 Million | 0.86x | 6.35x |
| 2020 | $229.86 Million | $1.06 Billion | $604.28 Million | 0.22x | 0.38x |
| 2021 | $300.95 Million | $654.84 Million | $426.03 Million | 0.46x | 0.71x |
| 2022 | $534.67 Million | $654.38 Million | $318.78 Million | 0.82x | 1.68x |
| 2023 | $462.64 Million | $767.67 Million | $274.65 Million | 0.60x | 1.68x |
| 2024 | $403.06 Million | $2.52 Billion | $1.75 Billion | 0.16x | 0.23x |
Competitor Companies of 4162 by Market Capitalization
Companies near PharmaEngine in the global market cap rankings as of May 4, 2026.
Key companies related to PharmaEngine by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
PharmaEngine Historical Marketcap From 2015 to 2026
Between 2015 and today, PharmaEngine's market cap moved from $629.29 Million to $ 245.05 Million, with a yearly change of -7.69%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$245.05 Million | -22.02% |
| 2025 | NT$314.24 Million | -22.04% |
| 2024 | NT$403.06 Million | -12.88% |
| 2023 | NT$462.64 Million | -13.47% |
| 2022 | NT$534.67 Million | +77.66% |
| 2021 | NT$300.95 Million | +30.93% |
| 2020 | NT$229.86 Million | -14.88% |
| 2019 | NT$270.03 Million | -38.54% |
| 2018 | NT$439.37 Million | -24.77% |
| 2017 | NT$584.01 Million | +1.75% |
| 2016 | NT$573.98 Million | -8.79% |
| 2015 | NT$629.29 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of PharmaEngine was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $245.05 Million USD |
| MoneyControl | $245.05 Million USD |
| MarketWatch | $245.05 Million USD |
| marketcap.company | $245.05 Million USD |
| Reuters | $245.05 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About PharmaEngine
PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan. It offers ONIVYDE, a cancer medicine that blocks an enzyme called topoisomerase I, which is involved in copying cell DNA needed to make new cells. The company is developing PEP07, a CHK1 inhibitor, which is in Phase 1 clinical trial for the treatment of hematol… Read more